We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.
Breakthrough Medicines for Fibrosis-Driven Diseases
Breakthrough Medicines for Inflammatory and Proliferative Diseases
Breakthrough Medicines for Fibrosis-Driven Diseases
Breakthrough Medicines for Inflammatory and Proliferative Diseases
Who We Are
Tvardi Therapeutics is a clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need.
Tvardi Press Releases
May 13, 2025
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 6, 2025
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
Tvardi Named 2021 Winner of Fierce 15 Biotech
Fierce Biotech has named Tvardi Therapeutics as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising biotechnology companies in the industry.